Evidence and guidelines are becoming increasingly clear about imbalance between the
risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected …

… β-Agonists were overused by 15.8% of moderately or severely symptomatic patients and
by … who overused inhaled β-agonists, 10.7% were not using any type of corticosteroid (inhaled …

… The aim of this study was to evaluate the relationship between inappropriate overuse of
inhaled corticosteroids and self-reported health status and the annual cost of patients with stable …

Methods Design, setting, participants, and data source. We conducted a cross-sectional
study using data collected through the COPD Outcomes-based Network for Clinical …

… Instead of defining nonadherence only as underuse, we also studied factors related to overuse
of ICS. Furthermore, we compared the perceptions of patients with underuse and overuse …

… However, in 4 out of 5 patients adherence to inhaled corticosteroid therapy and/or inhalation
technique was considered suboptimal. Since optimizing inhaler therapy may reduce the …

… who did not have an indication for an inhaled corticosteroid based on the most recent GOLD
… an appropriate indication for an inhaled corticosteroid. Appropriate indications included the …

… and examined the risks and costs associated with overuse. … (they were taking inhaled
corticosteroids and had not had an … they had not had inhaled corticosteroids were reclassified as …

… adequate doses of inhaled corticosteroids, and 40.3% had not received specialist intervention
within the previous 3 years. This suggests that OCS overuse is often underdiagnosed and …

… changes on indications for inhaled corticosteroids (ICS) … Rinne and colleagues state that
ICS overuse is very common … We agree with the statement regarding the overuse of ICS in …